Profluent Bio vs Synthekine
Side-by-side comparison of AI visibility scores, market position, and capabilities
AI protein design company released OpenCRISPR-1, the first gene editor designed entirely by AI; raised $35M developing novel enzymes, antibodies, and gene-editing tools by exploring protein sequence space beyond what evolution has produced.
About
Profluent Bio is an AI protein design company founded in 2022 by former Meta AI researcher Ali Madani, raising $35M in seed and Series A funding. The company trains large generative models on biological sequence data to design novel proteins with specific structural and functional properties, analogous to how large language models generate text. Profluent made scientific history in 2024 by publishing OpenCRISPR-1, the first gene editor designed entirely by AI rather than adapted from natural organisms, which the company released open source for non-commercial research. The platform enables design of novel enzymes, antibodies, and gene-editing tools by exploring protein sequence space far beyond what evolution has produced. Profluent works with pharmaceutical and agricultural biotechnology companies that need custom protein tools for research and therapeutic development. The company represents a fundamental advance in moving protein engineering from directed evolution and rational design toward generative AI-driven discovery.
Synthekine engineers selective cytokine therapeutics for cancer and autoimmune disease; $289M raised, Phase 2 SYNERGY-101 trial underway, FDA Fast Track for lupus program, 50% response rate in NSCLC Phase 1b.
About
Synthekine is a clinical-stage biotechnology company engineering next-generation cytokine therapeutics designed to harness the immune system's most powerful signaling molecules against cancer and autoimmune disease — without the severe toxicities that have historically limited cytokine drugs. Cytokines like interleukin-2 (IL-2) are known to activate potent anti-tumor immune responses, but their systemic pleiotropic effects cause dose-limiting toxicities when administered as conventional drugs. Synthekine's protein engineering platforms create partially agonized or receptor-selective cytokine variants that stimulate only the desired immune cell populations, dramatically improving the therapeutic window.
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Capabilities
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.